全文获取类型
收费全文 | 251篇 |
免费 | 20篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
基础医学 | 5篇 |
口腔科学 | 1篇 |
临床医学 | 26篇 |
内科学 | 68篇 |
皮肤病学 | 3篇 |
神经病学 | 12篇 |
特种医学 | 3篇 |
外科学 | 33篇 |
综合类 | 27篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 88篇 |
中国医学 | 3篇 |
肿瘤学 | 3篇 |
出版年
2024年 | 2篇 |
2023年 | 6篇 |
2022年 | 17篇 |
2021年 | 20篇 |
2020年 | 20篇 |
2019年 | 19篇 |
2018年 | 30篇 |
2017年 | 18篇 |
2016年 | 20篇 |
2015年 | 17篇 |
2014年 | 45篇 |
2013年 | 23篇 |
2012年 | 15篇 |
2011年 | 16篇 |
2010年 | 4篇 |
2009年 | 3篇 |
2008年 | 1篇 |
2007年 | 1篇 |
2005年 | 1篇 |
排序方式: 共有278条查询结果,搜索用时 15 毫秒
1.
《Reumatología clinica》2019,15(5):e33-e35
Antiphospholipid syndrome is characterized by abortions or thrombotic phenomena associated with specific antibodies. Anticoagulant therapy is based on vitamin K antagonists. We present two cases in which the use of rivaroxaban achieved control of the disease after the failure of acenocoumarol. 相似文献
2.
目的观察利伐沙班与低分子肝素钙预防髋关节置换术后深静脉血栓(DVT)形成的临床疗效。方法将2011年1月至2013年1月梅河口市中心医院收治的57例行髋关节置换术后的患者采用随机数字表法分为两组:肝素组(25例)采用低分子肝素钙抗凝治疗,利伐沙班组(32例)采用利伐沙班抗凝治疗,比较两组患者DVT、非致死性肺栓塞的发生例数,并记录血红蛋白和血小板计数变化情况。结果两组患者均未见非致死性肺栓塞,肝素组DVT和牙龈出血的发生率均高于利伐沙班组,差异有统计学意义(P<0.05);两组患者术前血红蛋白均较高,用药7 d后均下降,用药14d时又上升(P<0.05),两组患者血小板计数用药7 d均上升,用药14 d时又下降(P<0.05)。结论伐沙班在预防DVT方面有显著的临床疗效,适合于人工髋关节置换的患者,值得临床推广应用。 相似文献
3.
4.
《Heart rhythm》2019,16(8):e66-e93
5.
6.
7.
8.
Craig I. Coleman Alexander G.G. Turpie Thomas J. Bunz Jan Beyer-Westendorf William L. Baker 《The American journal of medicine》2019,132(4):498-504
Background
We sought to evaluate the real-world effectiveness and safety of prolonged anticoagulation with rivaroxaban following a provoked venous thromboembolism.Methods
Using US MarketScan claims from November 2012 to March 2017, we identified adults with ≥1 primary hospitalization or emergency department diagnosis code for venous thromboembolism, a provoking (major or minor, persistent or transient) risk factor, at least 3 months of continuous rivaroxaban treatment, and ≥12 months of continuous insurance benefits prior to their qualifying venous thromboembolism. Patients were categorized as either continuing rivaroxaban or discontinuing anticoagulation (no anticoagulation or nonaspirin antiplatelet agents but may have received aspirin) after the initial 3 months of rivaroxaban treatment (index date). Differences in baseline covariates between cohorts were adjusted for using inverse probability-of-treatment weights based on propensity scores (absolute standardized differences <0.1 achieved for all covariates after adjustment). Twelve month incidences of recurrent venous thromboembolism or major bleeding were compared between cohorts using Cox regression (according to an intention-to-treat methodology) and reported as hazard ratios (HRs) with 95% confidence intervals (CIs).Results
Among patients experiencing a provoked venous thromboembolism and treated with rivaroxaban for the first 3 months (N=4,990), continued rivaroxaban use beyond 3 months (median [25%, 75% range duration of additional rivaroxaban use?=?3 [2, 5] months) was associated with a 44% (95% CI of 9%-66%) lower hazard of recurrent venous thromboembolism without altering major bleeding risk [HR of 0.87, 95% CI of 0.51-1.49] versus anticoagulation discontinuation (with or without aspirin use).Conclusions
Our study suggests continuing rivaroxaban after the initial 3 month period was associated with a decreased risk of recurrent venous thromboembolism. The observed reduction in recurrent venous thromboembolism with prolonged rivaroxaban use was not associated with a significant change in major bleeding risk. 相似文献9.
目的:制备利伐沙班片剂,优选适合中试生产的最佳处方。方法通过设计不同处方,对增溶剂、崩解剂、黏合剂、填充剂的用量及工艺进行考察,并进行了中试三批放大,测定在四种溶出介质中的溶出曲线、含量均匀度和有关物质等指标。结果用利伐沙班为主药,以乳糖、微晶纤维素为填充剂,以十二烷基硫酸钠为增溶剂,以交联羧甲基纤维素钠为崩解剂,以羟丙基甲基纤维素为黏合剂、以硬脂酸镁为润滑剂,以胃溶型薄膜包衣预混剂为包衣材料,制得利伐沙班片。结论该制剂工艺稳定,制得利伐沙班片(10 mg)与原研市售品溶出行为相似,质量符合规定。 相似文献
10.
Carlos Escobar Julio Martí-Almor Alejandro Pérez Cabeza M. José Martínez-Zapata 《Revista espa?ola de cardiología》2019,72(4):305-316